Latest News
  • eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
  • Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support the Development of Personalized Therapeutics
  • Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing
  • eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
cancer treatment images
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement Belgium-based eTheRNA immunotherapies has established a collaboration and licence agreement with Ghent University for mRNA delivery with enhanced thermostability, biodegradability and safety. eTheRNA will receive worldwide commercialisation rights for the new generation of lipid nanoparticle (LNP) formulations co-developed with the university’s research group […]

Becton Dickinson & Company (BD) Bags IMAPAC’s Asia Bioprocessing Excellence Award 2022 and Recognized as The Best Bioprocessing Supplier Award: Formulation & Delivery Innovation

SINGAPORE – IMAPAC – 31 March 2022  BD, one of the largest global medical technology companies, has bagged the Asia Bioprocessing Excellence Award (ABEA) 2022 under the category Bioprocessing Supplier Award: Formulation & Delivery Innovation. The ABEA 2022 Ceremony was held in conjunction with the 9th Biologics Manufacturing Asia and 6th Biologistics World Asia 2022 […]

Vertex Announces Plan to Expand Cell and Gene Therapy Footprint

Excerpt Vertex Pharmaceuticals Incorporated has announced plans to set up another 344,000 sq ft facility in the Seaport to support the company’s continued rapid growth of its cell and genetic therapies programs. Article Summary The completion of the new site at Seaport is expected in 2025 following which Vertex will occupy 1.9 million square feet […]

Ultragenyx Acquires AAV gene therapy from Abeona Therapeutics Inc

Excerpt US based Biopharma Company, Ultragenyx has announced the acquisition AAV Gene Therapy (ABO-102) for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics. Article Summary ABO-102 (now UX111), is a novel gene therapy in Phase 1/2 development for Sanfilippo syndrome type A (MPS IIIA), a rare lysosomal storage disease with no approved treatment that […]

Transforming Cancer Treatment with Revolutionary CART – Cell Therapy – Story of Emily Whitehead Being Cancer Free

Article Summary In 2012, Emily Whitehead was diagnosed with acute lymphoblastic leukemia (ALL). After two years of unsuccessful chemotherapy and rapidly declining health, Emily became the first pediatric patient in the world to receive CAR T-cell therapy product called tisagenlecleucel or Kymriah and the first patient of any age to receive it for ALL. In […]

Avantor to Create a New Manufacturing and Distribution Hub in Singapore

Excerpt: Advanced technologies and applied materials provider, Avantor has announced the development of its new manufacturing and distribution hub in Singapore by integrating its existing distribution facility with new manufacturing operations.  Article Summary With the establishment of this new hub, Avantor aims to bring its solutions closer to regional customers and strengthens global supply chain […]

Vienna Airport sees pharma volumes grow as Austrian signs up to VPHC

Excerpt: Austrian Airlines has signed up to use the Vienna Airport Pharma Handling Center (VPHC) for all of its cargo volumes at the Austrian airport. Vienna Airport said the deal with the Lufthansa Group-owned airline would further establish the airport as a pharma hub for central and eastern Europe.   Article Summary: Vienna airport said […]

Nippon Express Obtains IATA CEIV Pharma Certification for Temperature-controlled Facility at Kansai International Airport

Excerpt: Nippon Express Co., Ltd. (hereinafter “Nippon Express”), a group company of Nippon Express Holdings, Inc., has obtained IATA CEIV Pharma (*) pharmaceutical transport quality certification, effective April 5, for its temperature-controlled facility “NX-PHARMA Logistics Hub Kansai Airport” located inside the international cargo area of Kansai International Airport.   Article Summary: Nippon Express has been […]

Cryoport Acquires Cell&Co BioServices

Excerpt: Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it has acquired Cell&Co BioServices, headquartered in Clermont-Ferrand, France with additional operations in Pont-du-Château, France. Founded in 2012, Cell&Co is a bioservices business providing biorepository, kitting, and logistics services to […]

COVID-19 and the Cold Chain: Lessons from the front lines of the vaccine rollout

Article Summary: Ensuring the safe handling, delivery and administration of more than a half-billion COVID-19 vaccines in the United States in less than two years was an unprecedented logistical feat. But distributing the two approved mRNA vaccines from Pfizer-BioNTech and Moderna has been a particular challenge, given the vaccines’ extreme temperature control requirements, according to […]

WTO members applaud the Quad document as a foundation for text-based pandemic IP response negotiations

Excerpt WTO members agreed on May 10 at a General Council meeting that the outcome document from the informal process with the Quad (European Union, India, South Africa, and the United States) opens the door to text-based talks on an intellectual property response to COVID-19. Members praised the proposal as a constructive step forward and […]

Moderna files for authorization of its COVID-19 Vaccine in young children six months to under six years of age

Excerpt Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that it has submitted an emergency use authorization (EUA) request to the US Food and Drug Administration for its COVID-19 vaccine (mRNA-1273) in children aged 6 months to under 2 years and 2 years to under 6 years, as well […]

IAVI and Moderna launch first-in-Africa clinical trial of mRNA HIV vaccine development program

Excerpt The nonprofit scientific research organization IAVI and Moderna, Inc, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant screenings are soon to start for a Phase I clinical trial of an mRNA HIV vaccine antigen (mRNA-1644) at the Center for Family Health Research (CFHR) in Kigali, Rwanda, […]

Explore IMAPAC

    We will send you occasional emails about our Events, Digital Marketing and Market Intelligence services, Upcoming Promotions and important updates about IMAPAC and its partners to keep you in the loop.

    By checking the box above, you acknowledge and agree to IMAPAC’s Terms of Service and to use your contact information provided to communicate with you about offerings by IMAPAC, its brands, affiliates and/or third-party partners consistent with IMAPAC’s Privacy Policy.


    Thought leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.


    In-depth biopharmaceutical industry intelligence brought to you by our team of analysts.

    LeadGen 360

    Expand your influence, be it through branding & display ads, content creation or thought leadership.


    Linking professionals and fostering conversations among the biopharmaceutical industry professionals.